Kay Hagan actually said...
One challenge that many of the witnesses today spoke of is the need to incentivize the device and drug/biotech industry to develop therapeutics for rare, pediatric diseases.
Context
Hagan emphasizes the need for incentives in developing treatments for rare pediatric diseases.
07/20/2010